Recent Stories

Advertorial

SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Approved by the State Council, the 2025 Sustainable Global Leaders Conference opened on October 16 in Huangpu District, Shanghai. Centered around the theme "Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth," the Co…

Advertorial

CHENGDU, China  , Oct. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblas…

Advertorial

SHANGHAI and HONG KONG, Oct. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematolog…

Advertorial

-          The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight.

Advertorial

HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) .  COMPASSION-15 is a Phase III clinical trial evaluating cadonilima…

Advertorial

BEIJING, Oct. 19, 2025 /PRNewswire/ -- The Annual Conference of Financial Street Forum (FSF) 2025 will open on October 27 and run through October 30 in Beijing, organizers announced at a press briefing on Friday. Themed "Global Financial Development in an Era of Innovation, Transformation an…

Advertorial

SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex genetic abnormalities. There is currently no standard treatment regimens, and conventional therapies for multiple myeloma are typi…

Advertorial
  • Updated

LUOYANG, China, Oct. 18, 2025 /PRNewswire/ -- On October 17, the 6th International Ancient Capitals Forum kicked off in Luoyang City, Henan Province. The event was attended by more than 150 participants, including government officials, experts and scholars, and international organization rep…

Advertorial

CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblas…

Advertorial

First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancerUnprecedented survival results from pivotal Phase 3 EV-303 trial show potential for PADCEV plus KEYTRUDA to redefine stand…

Advertorial

Rybelsus® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events (MACE) such as CV death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events1In…